Results 211 to 220 of about 2,394,761 (293)

ACCEPT Group Condensed Position Paper on the Management of Recurrent Pregnancy Loss

open access: yesAustralian and New Zealand Journal of Obstetrics and Gynaecology, EarlyView.
ABSTRACT The Australasian CREI (Certificate of Reproductive Endocrinology and Infertility) Consensus Expert Panel on Trial Evidence (ACCEPT) group recently published an evidence‐based guideline on the investigation and management of recurrent pregnancy loss (RPL).
Adriana Suker   +4 more
wiley   +1 more source

Prognosis After Seven Days of Veno‐Venous Extracorporeal Membrane Oxygenation Support

open access: yesArtificial Organs, EarlyView.
The hospital survival rate of patients still on V‐V ECMO after seven days was 45.1%. Survival correlates with the respiratory situation on day seven defined as points scored above the favorability margin of survival. Day 7 may be too early to predict prognosis in V‐V ECMO.
Felix A. Rottmann   +10 more
wiley   +1 more source

Vaping and Smoking in Pregnancy—A Meta‐Analysis of Neurobehavioural Development in Prenatally Exposed Offspring

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim Electronic cigarette usage has become increasingly popular in recent years, advertised as a safe alternative to smoking. However, the long‐term impact on prenatal development is not well understood. The aim of this systematic review and meta‐analysis is to investigate the impact of prenatal electronic cigarette exposure on self‐regulation ...
Abigail O'Connell   +9 more
wiley   +1 more source

Preferences between three options for androgen deprivation therapy: a focus group study

open access: yesBJU International, EarlyView.
Objectives Androgen deprivation therapy (ADT) forms the mainstay of treatment for advanced prostate cancer. Traditionally administered as a luteinising hormone‐releasing hormone (LHRH) agonist depot injection, newer options for ADT include transdermal oestradiol patches (tE2) or oral LHRH antagonists.
Hannah L. Rush   +13 more
wiley   +1 more source

Cannabinoid CB2 receptor‐mediated analgesia: mechanism‐based insights and therapeutic potential

open access: yesBritish Journal of Pharmacology, EarlyView.
Agonists of the cannabinoid 2 (CB2) receptor have shown promise for the treatment of pain in a variety of animal models. However, despite current preclinical evidence supporting the use of CB2 agonists for pain, successful translation of findings from preclinical models to human patients is lacking.
Kelsey G. Guenther, Andrea G. Hohmann
wiley   +1 more source

Home - About - Disclaimer - Privacy